Takeda to highlight research commitment in bleeding disorders and personalized care at american society of hematology (ash) virtual annual meeting

Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse: 4502/nyse:tak) today announced it will present nine company-sponsored abstracts at the 62nd american society of hematology (ash) annual meeting, being held virtually for the first time december 5-8, 2020. these data span takeda's extensive hematology portfolio and r&d pipeline, featuring results across various bleeding disorders, including hemophilia a, von willebrand disease and sickle cell diseas
TAK Ratings Summary
TAK Quant Ranking